Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
Photo of Sheila Gujrathi
Person

Sheila Gujrathi

Overview

Edit Overview Section
Number of Current Board & Advisor Roles 6
Number of Founded Organizations 1
Sheila Gujrathi serves as a Board Member at Ventyx Biosciences, IMMPACT BIO, ADARx Pharmaceuticals, and Janux Therapeutics.

Jobs

Edit Jobs Section
Number of Past Jobs 5
Sheila Gujrathi has had 5 past jobs including Co-Founder & Chief Executive Officer at Gossamer Bio.
Organization Name  
Title At Company  
Start Date  
End Date  
Gossamer Bio Logo
Gossamer Bio
Co-Founder & Chief Executive Officer20182020
Receptos Logo
Receptos
Chief Medical OfficerJun 2011Aug 2015
Bristol-Myers Squibb Logo
Bristol-Myers Squibb
Vice President of the Global Clinical Research Group in Immunology20082011
Genentech Logo
Genentech
Group Medical Director, Immunology Clinical Development20022007
McKinsey & Company Logo
McKinsey & Company
Management Consultant19992002

Board and Advisor Roles

Edit Board and Advisor Roles Section
Number of Current Board & Advisor Roles 6
Number of Past Board & Advisor Roles 2
Sheila Gujrathi holds 6 board and advisor roles including Director Board Of Directors at Janux Therapeutics, Executive Chair at Ventyx Biosciences, and Advisor & Investor at Ribo AI.
Organization Name  
Title At Company  
Start Date  
End Date  
Turning Point Therapeutics Logo
Turning Point Therapeutics
Board MemberDec 20172021
Five Prime Therapeutics Logo
Five Prime Therapeutics
Member of the Board of DirectorsDec 20152019

Education

Edit Education Section
Sheila Gujrathi studied at Northwestern University and  Northwestern University.

Recent News and Activity

Edit Recent News and Activity Section
Number of News Articles 11
News•Feb 26, 2021
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Nov 16, 2020
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jun 1, 2020
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jul 18, 2019
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jul 15, 2019
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jun 18, 2019
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jun 14, 2019
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Feb 17, 2019
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Feb 11, 2019
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Oct 2, 2018
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
View All
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(411cf44 1)
|